Načítá se...
Mortality reduction in 46 patients with severe COVID-19 treated with hyperimmune plasma. A proof-of-concept, single-arm, multicenter trial
Hyperimmune plasma from patients convalescing from COVID-19 is a potential treatment for severe COVID-19 in other patients. We conducted a multicenter, one-arm, proof-of-concept interventional study. Patients with COVID-19 with moderate-to-severe acute respiratory distress syndrome, elevated C-react...
Uloženo v:
| Vydáno v: | Haematologica |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Fondazione Ferrata Storti
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7716363/ https://ncbi.nlm.nih.gov/pubmed/33256382 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2020.261784 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|